4.8 Article

Complementarity-determining region clustering may cause CAR-T cell dysfunction

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Editorial Material Oncology

CAR T cells need a pitstop to win the race

Caitlin C. Zebley et al.

Summary: Early cessation of CAR T cell tonic signaling can prevent T cell exhaustion, leading to a prolonged anti-tumor response.

CANCER CELL (2021)

Review Oncology

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Sarwish Rafiq et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Article Biochemistry & Molecular Biology

Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties

Kento Fujiwara et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)

Article Biochemistry & Molecular Biology

Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases

Charlotta Preger et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Multidisciplinary Sciences

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Omar Khan et al.

NATURE (2019)

Article Multidisciplinary Sciences

TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion

Hyungseok Seo et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Review Oncology

Strategies to Address Chimeric Antigen Receptor Tonic Signaling

Adam Ajina et al.

MOLECULAR CANCER THERAPEUTICS (2018)

Article Medicine, General & Internal

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Biochemistry & Molecular Biology

Generation and analyses of human synthetic antibody libraries and their application for protein microarrays

Anna Sall et al.

PROTEIN ENGINEERING DESIGN & SELECTION (2016)

Article Oncology

Fine-tuning the CAR spacer improves T-cell potency

Norihiro Watanabe et al.

ONCOIMMUNOLOGY (2016)

Article Biochemistry & Molecular Biology

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Adrienne H. Long et al.

NATURE MEDICINE (2015)

Article Medicine, Research & Experimental

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors

Chuan Jin et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2014)

Article Biochemistry & Molecular Biology

Characterization and Immunotherapeutic Implications for a Novel Antibody Targeting Interleukin (IL)-13 Receptor α2

Irina V. Balyasnikova et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

Article Multidisciplinary Sciences

T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells

Victoria Hillerdal et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)